Skip to content
WeighLab

MEDVi vs Ivim Health

Compare the prices, treatment options and tradeoffs that matter before you choose a GLP-1 program.

By The WeighLab Bench. Provider verification dates appear below.

MEDVi

Provider comparison

Shoppers who want compounded semaglutide with no contract and are budgeting on the $299 refill price, not the first-month sale price.

Semaglutide / month
$299/moMonth-to-month refill price; first month $179, compounded
Tirzepatide / month
Not disclosed
Index 62/100 · Grade CChecked October 2026

Ivim Health

Provider comparison

Shoppers ready to commit to a multi-month program who want weekly check-ins, or insured shoppers who want help getting brand-name Wegovy or Zepbound covered.

Semaglutide / month
$149.99/mo6-month program, starting dose, medication and program fee, compounded
Tirzepatide / month
$207.99/mo6-month program, starting dose, medication and program fee, compounded
Index 61/100 · Grade CChecked October 2026

We may earn a commission if you sign up through a provider link, at no extra cost to you. Compensation does not change scores. How we earn money.

The comparison in brief

MEDVi has the higher Cost-Efficiency Index: 62/100 versus 61/100. That is a value comparison under our published methodology, not a measure of medical suitability or a guarantee of results.

Check the difference in state access

MEDVi
Not published
Ivim Health
Coverage not published

The better fit depends on what is included in your quote. A lower advertised price can require prepayment, apply to a starting dose or leave out a separate fee.

How the comparison is scored

Costs & coverage

Published prices with their terms intact. Annual estimates account for billing frequency and known fixed required fees; they are not a treatment quote.

MEDVi

Ivim Health

Semaglutide / month
MEDVi: $299/moMonth-to-month refill price; first month $179, compounded
Ivim Health: $149.99/mo6-month program, starting dose, medication and program fee, compounded
Tirzepatide / month
MEDVi: Not disclosed
Ivim Health: $207.99/mo6-month program, starting dose, medication and program fee, compounded
Semaglutide / year (modeled)
MEDVi: $3,588
Ivim Health: $1,800
Tirzepatide / year (modeled)
MEDVi: —
Ivim Health: $2,496
State availability
MEDVi: Not published
Ivim Health: Coverage not published
Oral / sublingual option listed
MEDVi: Yes
Ivim Health: Yes
Brand-name access listed
MEDVi: Yes
Ivim Health: Yes
Provider facts checked
MEDVi: October 2026
Ivim Health: October 2026

Comparing different billing plans? See what a GLP-1 monthly price can leave out, or calculate the monthly cost.

Which program fits your priorities?

The strengths and limitations behind each provider's score. Read the full review before deciding.

MEDVi

Shoppers who want compounded semaglutide with no contract and are budgeting on the $299 refill price, not the first-month sale price.

Reasons to consider it

  • The FAQ states both numbers plainly: $179 for the first month and refills locked in at $299, covering the provider review, the medication and shipping
  • No contract; you can cancel at any time by email or through the patient portal chat
  • Names its partner pharmacies (Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding) and the medical groups behind its providers

What to weigh up

  • The $179 headline is a first-month "FALL Sale" price; every refill after that is $299
  • Cancellation must reach support at least 72 hours before your next billing date, and monthly charges are never refunded once the month has started
  • No state list is published; the terms say to contact customer service to find out whether your state is served

Regulatory note: the FDA issued a warning letter to MEDVi, LLC dba MEDVi in February 2026. We still list and link to MEDVi; you should know the letter is on the public record before you decide.

Ivim Health

Shoppers ready to commit to a multi-month program who want weekly check-ins, or insured shoppers who want help getting brand-name Wegovy or Zepbound covered.

Reasons to consider it

  • Publishes six-month rates: compounded semaglutide $75 and tirzepatide $133 a month, plus the $74.99 monthly program fee
  • Also prescribes brand-name Wegovy, the Wegovy pill, Foundayo, Zepbound and others, with an insurance team that handles prior authorizations
  • Weekly app check-ins and refills timed to your plan, with dose adjustments by your provider

What to weigh up

  • Programs run one, two, four or six months, and the FAQ says you can't cancel once a program starts; leaving early can cost $50 or $100 per unshipped portion
  • No month-to-month price is published: the advertised rates are six-month rates, and the cost at a higher dose isn't shown
  • Doesn't name its pharmacy or list the states it serves

Regulatory note: the FDA issued a warning letter to Ivim Services LLC dba Ivim in February 2026. We still list and link to Ivim Health; you should know the letter is on the public record before you decide.

Explore the six scoring factors

Scores run from 0 to 100. A higher factor score reflects our published value criteria; it is not a clinical endorsement.

MEDViIvim Health
Normalized Cost/Month
MEDVi:
50/100
Ivim Health:
62/100
Price Transparency
MEDVi:
92/100
Ivim Health:
78/100
Nationwide Access
MEDVi:
24/100
Ivim Health:
24/100
Formulation Options
MEDVi:
77/100
Ivim Health:
95/100
Clinical Oversight
MEDVi:
70/100
Ivim Health:
79/100
Contract Flexibility
MEDVi:
67/100
Ivim Health:
20/100

Before you sign up

  • Confirm your totalAsk about dose changes, membership, labs, shipping and cancellation terms.
  • Check treatment accessState coverage and medical eligibility can differ by medication and formulation.
  • Understand the medicationCompare compounded and brand-name options. Compounded drugs are not FDA-approved.

Keep comparing

More provider matchups
Choose a different comparison

Provider information reflects public disclosures at the verification dates shown. Prices and availability change; confirm current terms before paying. This comparison is for information, not medical advice. A licensed clinician determines whether treatment is appropriate.